Table 2 Prognostic factors of PFS in 141 patients with early-stage disease from the training set and 69 patients in the validation set.

	Progression-free survival
	Discovery set (n = 141)			Validation set (n = 69)
	HR	95% CI	P	HR	95% CI	P
TCF of >25%	4.9	2.5–9.7	<0.001	10	3.4–31	<0.001
Stage (IB versus IA)	2.5	1.3–4.9	0.008	6.4	1.5–28	0.01
Presence of plaques	2.2	1.1–4.2	0.02	1.9	0.8–4.4	0.15
Elevated LDH levels	1.2	0.4–3.1	0.8	1.0	0.3–3.4	1
Large-cell transformation	1.5	0.4–6.4	0.6	1.6	0.2–12	0.6
Age (>60 years)	2.0	1.0–3.7	0.04	1.3	0.5–3.0	0.6
CLIPI score*
Intermediate risk (versus low)	2.2	1.0–5.0	0.05	0.4	0.1–2.0	0.2
High risk (versus low)	3.5	1.6–7.7	0.002	2.3	0.9–5.9	0.07

*The CLIPI was calculated on the basis of the presence of the following factors: age (>60 years), male sex, plaques, folliculotropism, and clinical adenopathy N1/Nx; low risk = 0 to 1, intermediate risk = 2, and high risk = 3 to 5 prognostic factors.